Michaela H.
- Country
- Ireland
- Department
- Medical Oncology
Research Overview
- Phase 3 Study of Sacituzumab Tirumotecan and Pembrolizumab Versus Physician's Choice in HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
- Phase 3b/4 Study of Trastuzumab Deruxtecan in HER2-Positive Breast Cancer Patients With or Without Brain Metastasis After Prior Treatment
- Phase 2 Trial of Neoadjuvant Trastuzumab Deruxtecan in Early Stage HER2-Positive Breast Cancer with Response-Directed Therapy
Data & Insights
Has run more than one trial at 52 of 285 partner sites.
Specializations
Breast Cancer Therapeutics
The investigator specializes in treating HER2-positive breast cancer, with particular focus on developing innovative therapeutic approaches in both early-stage and metastatic settings.
- Neoadjuvant Treatment Strategies
- Brain Metastasis Management
- Hormone Receptor Positive Disease
Their research encompasses targeted therapies including trastuzumab deruxtecan for various stages of breast cancer treatment.
Gastrointestinal Medicine
The investigator conducts research in inflammatory bowel conditions, with specialized expertise in treating Crohn's Disease.
- Maintenance Therapy Development
- Long-term Disease Management
- Therapeutic Drug Monitoring
Their work includes evaluation of novel biological therapies such as risankizumab for moderate to severe disease states.
Immunotherapy Applications
The investigator explores combination therapy approaches in oncology, integrating immunotherapy with conventional treatments.
- Advanced Breast Cancer Treatment
- Unresectable Disease Management
- Novel Therapeutic Combinations
Their research includes investigating pembrolizumab combinations in treatment-resistant breast cancer.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.